Innate Pharma highlights proprietary tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 congress
SAR'579 / IPH6101 receives FDA Fast Track Designation in the US for the treatment of hematological malignancies
Number of shares and voting rights of Innate Pharma as of June 1, 2023
Innate Pharma highlights Phase 1/2 dose escalation safety and preliminary efficacy of Sanofi developed first NK Cell Engager SAR'579 / IPH6101 in R/R AML
Innate Pharma to participate in upcoming investor conferences
Innate Pharma to present IPH6501 preclinical data at the EHA 2023 congress
Outcome of Innate Pharma’s 2023 Annual General Meeting
Innate Pharma Reports First Quarter 2023 Financial Results And Business Update
Number of shares and voting rights of Innate Pharma as of May 1, 2023
Innate Pharma highlights clinical abstracts selected for ASCO 2023 annual meeting
